BRAF and melanoma: Moreover, mutant BRAF colon cancer cells are largely unresponsive to clinically available mutant BRAF inhibitors including vemurafenib and dabrafenib, although these inhibitors have achieved impressive clinical response rates in the treatment of patients with mutant BRAF melanomas [39, 40].